![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
"IRIDEX is the leading worldwide provider of semiconductor-based laser systems used to treat eye diseases, including the leading causes of irreversible blindness. The primary treatment of many eye diseases (such as macular degeneration, glaucoma, retinal detachments, and ocular tumors) is photocoagulation, the minimal heating of the ocular tissue to create a therapeutic response. The company's OcuLight System is an alternative to photocoagulator systems that use vacuum tubes. The system is sold worldwide, primarily to hospitals for use by ophthalmic specialists. Approximately half of the company's revenues come from international sales in 63 countries." Looks like the OcuLight GL is selling well now and the supply problems are closed to being resolved. Though IRIX experienced growing pains in 1996, the new year promises to be much more positive and they have positioned themselves for growth. Not only are they helping the world, but IRIX looks like a great buy right now. There are only 6mil shares outstanding and the market cap is under $50 million, SO WATCH OUT! With that small of a float, if this one gets hot, it could easily (yes, I said easily) be in the $20-$30 range by the end of the year. Welcome to the IRIX thread. | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |